Open AccessInhibition of glutathione metabolism can limit the development of pancreatic cancer
Author(s) -
Peiyuan Cai,
Mei-Lin Ma,
Yang-Fen Zhang,
Zixuan Zhou,
Yan Wang,
Lianping He,
Wei Wang
Publication year - 2022
Publication title -
world journal of stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 18
ISSN - 1948-0210
DOI - 10.4252/wjsc.v14.i5.362
Subject(s) - glutathione , buthionine sulfoximine , pancreatic cancer , reactive oxygen species , apoptosis , cancer cell , cancer research , metabolism , cancer , medicine , pharmacology , chemistry , biochemistry , enzyme
Pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine, inhibit glutathione metabolism. These drugs decrease the aggressiveness of pancreatic cancer, inhibit tumor stem cell survival, and reduce chemotherapy resistance. Nevertheless, buthionine-sulfoximine also decreases the content of glutathione in normal cells, disrupts the balance between reactive oxygen species and glutathione, and eventually induces cell apoptosis. Pancreatic cancer is usually diagnosed at an advanced stage and has a poor prognosis. Consequently, the use of biomarkers to screen high-risk patients can be an effective method.